1 Combination therapy with the AGE cross-link breaker, alagebrium and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy? Short Title: Combination therapy with Alagebrium and ACEi Melinda T Coughlan 1 , Vicki Thallas-Bonke 1 , Josefa Pete 1 , David M Long 1 , Anna Gasser 1 , David CK Tong 1 , Maryann Arnstein 1 , Suzanne R Thorpe 2 , Mark E Cooper 1,3 , Josephine M Forbes 1,3 . 1 Albert Einstein JDRF Centre for Diabetes Complications, Wynn Domain, Baker Medical Research Institute, Melbourne, Victoria, Australia. 2 Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina USA. 3 Department of Immunology, Monash University, AMPREP Precinct, Melbourne, Victoria, Australia. Correspondence and reprints should be addressed to: Dr M. T. Coughlan Albert Einstein JDRF Centre for Diabetes Complications Wynn Domain Baker Medical Research Institute P.O Box 6492 St Kilda Rd Central Melbourne, Victoria, Australia, 8008 Ph: 61 03 8532 1278 Endocrinology. First published ahead of print November 16, 2006 as doi:10.1210/en.2006-1300 Copyright (C) 2006 by The Endocrine Society